Permeation enhancers
View Patent ↗A pharmaceutical composition comprising a drug and a permeation enhancer that comprises a multi-carbon backbone having a functional group and also one or more side chains which have one or more carbon atoms and, optionally, one or more functional groups.
1. A pharmaceutical composition comprising:
(a) a hydrophilic or macromolecular drug having poor membrane permeability;
(b) a branched chain permeation enhancer comprising an acid functional group-containing compound of Formula I in which at least 50% of the total number of acid functional groups present have been reacted with a base, the compound of Formula I comprising:
wherein,
Q is a partially or completely neutralized —COOH functional group,
R 1 is C 6-8 alkyl,
R 2 is C 8-10 alkyl,
and wherein the permeation enhancer is present in an amount sufficient to increase the bioavailability of the drug upon transdermal or transmucosal administration to a patient; and
(c) optionally, other pharmaceutically acceptable ingredients.
2. The pharmaceutical composition of claim 1 wherein said permeation enhancer is a compound of Formula I, wherein:
Q is —COONa
R 1 is —C 6 straight chain alkyl, and
R 2 is —C 8 straight chain alkyl.
3. The pharmaceutical composition of claim 1 wherein said permeation enhancer is a compound of Formula I wherein:
Q is —COONa
R 1 is —C 8 straight chain alkyl, and
R 2 is —C 10 straight chain alkyl.
4. The pharmaceutical composition of claim 1 wherein said drug is selected from the group consisting of proteins, peptides, and antigens.
5. The pharmaceutical composition of claim 1 wherein said drug is heparin.
6. The pharmaceutical composition of claim 1 wherein the hydrophilic or macromolecular drug having poor membrane permeability is a Class III or a Class IV drug.
7. The pharmaceutical composition of claim 6 wherein the Class III or Class IV drug is selected from the group consisting of furoseamide, low molecular weight heparin, nucleotides, peptides, proteins, growth hormone, calcitonin, enalaprilate, acyclovir, leuprolide acetate, antisense oligonucleotides, ribozymes, external guide sequence oligonucleotides, and RNAs.
8. The pharmaceutical of claim 1 , wherein said pharmaceutical is in a form for transmucosal delivery and wherein the permeation enhancer is present in an amount sufficient to increase the bioavailability of the drug upon transmucosal administration to a patient.
9. The pharmaceutical composition of claim 8 , wherein the drug is a Class III or a Class IV drug.
10. The pharmaceutical composition of claim 8 , wherein said form for transmucosal administration is selected from the group consisting of: a form for aerosol delivery of the drug to the nose or lungs; and a form for oral ingestion of the drug followed by permeation through the gastrointestinal wall.
11. The pharmaceutical composition of claim 9 wherein the Class III or Class IV drug is selected from the group consisting of furoseamide, low molecular weight heparin, nucleotides, peptides, proteins, growth hormone, calcitonin, enalaprilate, acyclovir, leuprolide acetate, antisense oligonucleotides, ribozymes, external guide sequence oligonucleotides, and RNAs.
12. The pharmaceutical composition of claim 1 , wherein said composition is in a form for transdermal delivery and wherein the permeation enhancer is present in an amount sufficient to increase the bioavailability of the drug upon transdermal administration to a patient.
13. The pharmaceutical composition of claim 12 , wherein the hydrophilic or macromolecular drug having poor membrane permeability is a Class III or a Class IV drug.
14. The pharmaceutical composition of claim 12 , wherein said form for transdermal administration is selected from the group consisting of: a solid form; a liquid form; and a gel form, and wherein said composition is suitable for application through the skin by use of a transdermal patch.
15. The pharmaceutical composition of claim 13 wherein the Class III or Class IV drug is selected from the group consisting of furoseamide, low molecular weight heparin, nucleotides, peptides, proteins, growth hormone, calcitonin, enalaprilate, acyclovir, leuprolide acetate, antisense oligonucleotides, ribozymes, external guide sequence oligonucleotides, and RNAs.
16. A method of providing for enhanced uptake of a hydrophilic or macromolecular drug having poor membrane permeability in the gastrointestinal tract of an animal, the method comprising providing an oral dosage form containing a therapeutically effective amount of the pharmaceutical composition of claim 12 , wherein said composition is in a form for transmucosal delivery by permeation through the gastrointestinal wall.
17. A method of administering a hydrophilic or macromolecular drug having poor membrane permeability to a patient in need thereof comprising administering to the patient the pharmaceutical composition of claim 1 containing said drug and said permeation enhancer of Formula I wherein the permeation enhancer is present in an amount sufficient to increase the bioavailability of the drug upon transdermal or transmucosal administration to a patient.
18. The method of claim 17 wherein Q is —COONa, R 1 is —C 6 straight chain alkyl, and R 2 is —C 8 straight chain alkyl.
19. The method of claim 17 wherein Q is —COONa, R 1 is —C 8 straight chain alkyl, and R 2 is —C 10 straight chain alkyl.
20. A method of administering a hydrophilic or macromolecular drug having poor membrane permeability to a patient in need thereof comprising administering to the patient the composition of claim 8 containing said drug and said permeation enhancer wherein the permeation enhancer is present in an amount sufficient to increase the bioavailability of the drug upon transmucosal administration to a patient.
21. A method of administering a hydrophilic or macromolecular drug having poor membrane permeability to a patient in need thereof comprising administering to the patient the composition of claim 12 containing said drug and said permeation enhancer wherein the permeation enhancer is present in an amount sufficient to increase the bioavailability of the drug upon transdermal administration to a patient.